Previous 10 | Next 10 |
Continued progress on FUROSCIX ® ; confirming the planned resubmission of FUROSCIX ® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies Completed $20.0 million term loan with Solar Capital Ltd. and Sili...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. The Bounce/Lag...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
In a update to investors, scPharmaceuticals ( SCPH -0.6% ) says that it remains on schedule to resubmit its U.S. marketing application for lead candidate FUROSCIX for the treatment of congestion in heart failure patients by mid-2020. More news on: scPharmaceuticals Inc., Healthcare sto...
Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank BURLINGTON, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasda...
Reviewing the Damage Many highly popular stocks suffered a sudden and brutal sell-off this week, a reversal that analysts have already dubbed the "momentum crash". The blow was particularly strong in the US, where strong-momentum stocks - those with the best recent record - tumbled 4 per ce...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
The following slide deck was published by scPharmaceuticals Inc. in conjunction with this Read more ...
scPharmaceuticals (NASDAQ: SCPH ): Q2 GAAP EPS of -$0.39 beats by $0.09 . More news on: scPharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission Company successfully completed the first of two planned human factors studies Company accelerates timeline ...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...